Summit Therapeutics (SMMT) Non Operating Income (2020 - 2026)

Summit Therapeutics (SMMT) has 7 years of Non Operating Income data on file, last reported at $4.8 million in Q2 2026.

• Quarterly Non Operating Income rose 75.74% year-over-year to $4.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $18.8 million (up 19.73% YoY) and the FY2025 annual result came in at $14.8 million, up 10.99% from the prior year.
• Non Operating Income retreated to $4.8 million in Q2 2026, from $5.8 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $16.1 million in Q4 2023 to a low of -$5.2 million in Q1 2023.
• A 5-year average of $2.6 million and a median of $2.6 million in 2025 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2022 — Non Operating Income sank 3833.63% — and 2024, when it soared 689.95%.
• Tracing SMMT's Non Operating Income over 5 years: stood at $5.5 million in 2022, then surged by 194.35% to $16.1 million in 2023, then plunged by 72.55% to $4.4 million in 2024, then jumped by 30.16% to $5.8 million in 2025, then retreated by 16.63% to $4.8 million in 2026.
• The last three Non Operating Income figures came in at $4.8 million (Q2 2026), $5.8 million (Q1 2026), and $5.8 million (Q4 2025), per Business Quant data.